PXT00864

Pharnext S.C.A. · Phase 2 active Small molecule

At a glance

Generic name	PXT00864
Sponsor	Pharnext S.C.A.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD) (PHASE2)
24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PXT00864 CI brief — competitive landscape report
PXT00864 updates RSS · CI watch RSS
Pharnext S.C.A. portfolio CI